NAS10031,076+0.87%S&P7,774+0.66%GOLD$4,187+0.74%BTC$86,155+0.43%VIX15.36−1.03%live tape · as of 11:01 UTC
The Screen · Financials · Insurance - Life
Samsung Life Insurance
032830.KS · KRX · KRW · Market cap $69.23T
Samsung Life Insurance Co., Ltd., together with its subsidiaries, engages in the life insurance business to corporate and individual customers in South Korea and internationally.
FAIL · Does not pass the screen
283,500.00 KRW
Screen close, 2026-09-18 · not a live quote Last reviewed 18 days ago
Screened 2026-09-18 · the tape above runs as of 11:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 283,500.00 against the desk's fair-value range, base estimate 348,000.00, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price283,500.00 KRW
Fair value348,000.00
Ethical score30.0/100
RatingAVOID
Our investment reviews on this name
2026-10-02Read Distribution283,500.00+0.0% to today
2026-09-12Read Markup385,500.00-26.5% to today
2026-08-05Read Distribution385,500.00-26.5% to today ✓
2026-07-19Read Markup385,500.00-26.5% to today
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Samsung Life Insurance holds its Distribution at $283,500.00. Elevated stress, defensive posture warranted, held for 1 days.
As held on the ledger · 2026-09-18
Phase
Distribution · caution
Quantitative state
Elevated stress, defensive posture warranted, held for 1 days
Price at the screen
$283,500.00
Valuation
N/A trailing · 18.24 forward price to earnings
Values screen
FAIL· score 30.0
The Workings
Five Screens, Shown in Full
Does not pass. Business activity screen
Test
Figure
Limit
What it means
Status
Business activity
Excluded
Core business clean
Insurance — FAIL on business activity
Fail
Debt load
6.59%
Below 33%
Interest-bearing debt is just 6.6% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
1.70%
Below 33%
Cash held in interest-bearing accounts and securities is 1.7% of assets, under the one-third limit.
Pass
Receivables
0.01%
Below 49%
Money owed to the company is 0.0% of assets, under the 49% limit.
Pass
Revenue purity
-6.70%
Below 5%
Only -6.7% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Samsung Life Insurance does not clear the screen at the business-activity stage. It operates in conventional financial services, which the screen treats as interest-based, so the financial ratios are not the deciding factor here.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads AVOID: it trades at roughly a 23% discount to our $348,000.00 fair value, 59.30% revenue growth.
Fair value range in KRW, drawn from the 2026-09-18 screen. The gold marker is the market price at the same screen. A 22.8% margin of safety to the base estimate.
Third-party analyst targets: 18 covering, consensus Buy. The average target sits +23% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-18 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why it gives us pause
At 18.2x forward earnings, the price already runs ahead of the business. Our fair value sits at $348,000.00, below where it trades today.
The risks · The things to watch: its business and earnings are exposed to South Korea and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
032830.KS trades on KRX (the company is based in South Korea). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 26.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 89% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 227%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (18 analysts) rates it buy, with a mean price target of $358472. Since the last review it its composite score rose.
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 89% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 227%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (18 analysts) rates it buy, with a mean price target of $358472.
2026-08-12Distribution$385,500.00+0.0%Entry 12
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 89% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 227%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (18 analysts) rates it buy, with a mean price target of $358472. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-11Distribution$385,500.00+0.0%Entry 11
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 89% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 227%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (18 analysts) rates it buy, with a mean price target of $358472. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-09Distribution$385,500.00+0.0%Entry 10
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 89% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 227%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (18 analysts) rates it buy, with a mean price target of $358472. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-08Distribution$385,500.00+0.0%Entry 9
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 89% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 227%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (18 analysts) rates it buy, with a mean price target of $358472. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-07Distribution$385,500.00+0.0%Entry 8
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 89% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 227%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (18 analysts) rates it buy, with a mean price target of $358472. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-06Distribution$385,500.00+0.0%Entry 7
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 89% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 227%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (18 analysts) rates it buy, with a mean price target of $358472. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 89% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 227%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (18 analysts) rates it buy, with a mean price target of $358472. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-19Markup$385,500.00+0.0%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 89% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 227%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (18 analysts) rates it buy, with a mean price target of $358472.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$299,500.00
+22.9%
·
$1,229
+22.9%
2 months
$234,500.00
+56.9%
·
$1,569
+56.9%
3 months
$218,500.00
+68.4%
·
$1,684
+68.4%
6 months
$150,428.31
+144.6%
$5,300.00
$2,482
+148.2%
1 year
$112,410.09
+227.4%
$5,300.00
$3,321
+232.1%
2 years
$77,252.16
+376.4%
$9,800.00
$4,890
+389.0%
3 years
$59,656.17
+516.9%
$13,500.00
$6,395
+539.5%
5 years
$65,768.72
+459.5%
$19,500.00
$5,892
+489.2%
Historical returns from market close data. Past performance does not guarantee future results.
The Ledger's Promise
This entry now belongs to the ledger. Whatever 032830.KS does next, these words stay.
Samsung Life Insurance · 032830.KS · Distribution · $283,500.00
Recorded 2026-09-18 · before the outcome · scored mechanically